AI Engines For more Details: Perplexity Kagi Labs You
Hypertension (High Blood Pressure): Nisoldipine works by inhibiting the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation (widening of blood vessels). This results in decreased peripheral resistance and a reduction in blood pressure. It is commonly prescribed as a first-line treatment for hypertension.
Chronic Stable Angina: Nisoldipine may also be used in the management of chronic stable angina, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. By dilating coronary arteries, nisoldipine can increase myocardial oxygen supply and reduce the frequency and severity of angina episodes.
Vasospastic Angina (Prinzmetal's Angina): Nisoldipine is sometimes used off-label for the treatment of vasospastic angina, also known as Prinzmetal's angina. It helps alleviate symptoms by dilating coronary arteries and improving blood flow to the heart muscle during vasospastic episodes.
Raynaud's Phenomenon: In some cases, nisoldipine may be prescribed off-label for the management of Raynaud's phenomenon, a condition characterized by episodic vasospasm of the small arteries, typically in the fingers and toes. Vasodilation induced by nisoldipine can help improve blood flow to the affected areas and reduce symptoms such as pain and numbness.
Migraine Prophylaxis: Some evidence suggests that calcium channel blockers like nisoldipine may have a role in preventing migraine headaches, particularly those associated with vasospasm. However, more research is needed to establish its efficacy and safety for this indication.
Diastolic Heart Failure: Nisoldipine may be considered in the management of diastolic heart failure, a condition characterized by impaired relaxation of the heart muscle during diastole. By reducing systemic vascular resistance, it can help improve ventricular filling and decrease left ventricular diastolic pressure.
Renal Protection: Some studies suggest that calcium channel blockers like nisoldipine may have renal protective effects in patients with chronic kidney disease, particularly in those with proteinuria. By lowering blood pressure and reducing intraglomerular pressure, they may slow the progression of kidney damage.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.7 | 0.6 | 5.17 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 1.7 | 0.29 |
| Allergies | 4.9 | 1.6 | 2.06 |
| Allergy to milk products | 1.2 | 1.6 | -0.33 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.2 | 6.3 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.2 | 11 |
| Ankylosing spondylitis | 3.6 | 0.3 | 11 |
| Anorexia Nervosa | 1.3 | 2.5 | -0.92 |
| Antiphospholipid syndrome (APS) | 1.3 | 1.3 | |
| Asthma | 4 | 1.9 | 1.11 |
| Atherosclerosis | 1.5 | 1.8 | -0.2 |
| Atrial fibrillation | 2.8 | 2.8 | 0 |
| Autism | 8.5 | 7.1 | 0.2 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 1.8 | 1.4 | 0.29 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.6 | 2 | -2.33 |
| Carcinoma | 2.9 | 1.7 | 0.71 |
| Celiac Disease | 2.8 | 1.9 | 0.47 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 3.9 | 5.7 | -0.46 |
| Chronic Kidney Disease | 4 | 2.3 | 0.74 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.4 | 0.5 |
| Chronic Urticaria (Hives) | 1.5 | 1.1 | 0.36 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1 | 0.5 |
| Cognitive Function | 1.6 | 1.6 | 0 |
| Colorectal Cancer | 6 | 2.4 | 1.5 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.6 | 2.9 | -0.81 |
| COVID-19 | 8.1 | 9.2 | -0.14 |
| Crohn's Disease | 6.7 | 3.6 | 0.86 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.5 | -0.88 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.5 | 1.1 | 0.36 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 8.7 | 7 | 0.24 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 2 | -0.43 |
| Endometriosis | 2.5 | 1.6 | 0.56 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.2 | 1.7 | 0.88 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 2.5 | 2.6 | -0.04 |
| Functional constipation / chronic idiopathic constipation | 5.1 | 4.5 | 0.13 |
| gallstone disease (gsd) | 2.3 | 0.8 | 1.87 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.9 | 0.56 |
| Generalized anxiety disorder | 2.1 | 1.5 | 0.4 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.7 | 0.5 | 2.4 |
| Graves' disease | 1.6 | 2.4 | -0.5 |
| Gulf War Syndrome | 0.9 | 1.2 | -0.33 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.6 | 1.2 | 1.17 |
| Heart Failure | 2.9 | 1.6 | 0.81 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 1.6 | 0.3 | 4.33 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
| hyperglycemia | 1.6 | 1.1 | 0.45 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.5 | 3.5 | 0 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 2.6 | 0.3 | 7.67 |
| IgA nephropathy (IgAN) | 1.3 | 3.9 | -2 |
| Inflammatory Bowel Disease | 7.1 | 7.4 | -0.04 |
| Insomnia | 1.8 | 1.8 | 0 |
| Intelligence | 1.6 | 0.6 | 1.67 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 5.9 | 4.7 | 0.26 |
| ischemic stroke | 2.1 | 1.7 | 0.24 |
| Liver Cirrhosis | 5.8 | 2.4 | 1.42 |
| Long COVID | 6.2 | 4.9 | 0.27 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.2 | 0.1 | 11 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.9 | 1.8 | -1 |
| ME/CFS without IBS | 1.1 | 1.2 | -0.09 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 0.5 | 1.6 |
| Metabolic Syndrome | 5.8 | 5.6 | 0.04 |
| Mood Disorders | 8.9 | 6.8 | 0.31 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 6.2 | 5.4 | 0.15 |
| Multiple system atrophy (MSA) | 0.6 | 0.4 | 0.5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.4 | -7 |
| Neuropathy (all types) | 0.7 | 2.2 | -2.14 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.1 | 3.4 | 0.21 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 7.3 | 5.1 | 0.43 |
| obsessive-compulsive disorder | 5.6 | 3.1 | 0.81 |
| Osteoarthritis | 2.2 | 0.9 | 1.44 |
| Osteoporosis | 2.2 | 0.7 | 2.14 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.4 | 5.4 | 0.37 |
| Polycystic ovary syndrome | 6 | 2 | 2 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.6 | 1.4 | -1.33 |
| Primary sclerosing cholangitis | 2.4 | 2.3 | 0.04 |
| Psoriasis | 2.5 | 3.4 | -0.36 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 3.7 | 0.3 |
| Rosacea | 0.9 | 0.7 | 0.29 |
| Schizophrenia | 5 | 2.5 | 1 |
| scoliosis | 0.5 | 0.5 | |
| Sjögren syndrome | 2.9 | 2.2 | 0.32 |
| Sleep Apnea | 0.7 | 1.5 | -1.14 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.3 | 1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.2 | 6.5 |
| Stress / posttraumatic stress disorder | 1.9 | 2.5 | -0.32 |
| Systemic Lupus Erythematosus | 4.1 | 1.3 | 2.15 |
| Tic Disorder | 1.2 | 1.2 | 0 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 3.8 | 3 | 0.27 |
| Type 2 Diabetes | 7.2 | 5.6 | 0.29 |
| Ulcerative colitis | 4.5 | 6.4 | -0.42 |
| Unhealthy Ageing | 4.1 | 2.4 | 0.71 |
| Vitiligo | 1.8 | 1.5 | 0.2 |
